[Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain].
To evaluate the safety and efficacy of strontium-89-chloride for management of bone metastases in patients without bone pain. Fifty-four patients without painful bone metastases were given a single intravenous dose (1.48-2.22 MBq/kg) of strontium-89-chloride, which was repeated once or twice at the interval between 3 and 6 months. The total response rate was 74.0% in these, and the response rate was significantly lower in patients with focal size>2 cm than in those with focal size<or=2 cm (33.3% vs 66.6%, chi2=14.9, P<0.01). The side effects of strontium-89-chloride included mainly thrombocytopenia and neutropenia, mostly mild and reversible without interventions. Strontium-89-chloride is effective and safe for treatment of nonpainful bone metastases.